PP
RIGL icon

PDT Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

PDT Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,809
Closed -$371K – 705
2025
Q2 		$371K Sell
19,809
-6
-0% -$114 0.02% 565
2025
Q1 		$356K Sell
19,815
-14
-0.1% -$284 0.03% 582
2024
Q4 		$334K Sell
19,829
-85
-0.4% -$1.63K 0.03% 556
2024
Q3 		$322K Buy
+19,914
New +$234K 0.03% 586

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CLGM
Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PDT Partners's RIGL Position: Q3 2025 in Review

PDT Partners sold out of Rigel Pharmaceuticals (RIGL) in Q3 2025, closing a stake of 19,809 shares — an estimated $371K sold.

PDT Partners first reported a position in RIGL in Q3 2024 and held it in 4 quarters. The position peaked at $371K in Q2 2025. 169 funds tracked by Wall St. Rank hold RIGL as of Q3 2025.

  • PDT Partners reported no remaining Rigel Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • PDT Partners sold 19,809 Rigel Pharmaceuticals shares in Q3 2025, an estimated $371K.
  • PDT Partners first reported a position in Rigel Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • PDT Partners's Rigel Pharmaceuticals position peaked at $371K in Q2 2025.
  • 169 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2025.

Based on PDT Partners's 13F filing for Q3 2025, filed 17 Nov 2025.